Literature DB >> 16451099

Indapamide sustained release: a review of its use in the treatment of hypertension.

Dean M Robinson1, Keri Wellington.   

Abstract

A low-dose sustained-release (SR) formulation of the thiazide-type diuretic indapamide, indapamide SR (Natrilix SR), retains the antihypertensive activity of the immediate-release (IR) formulation, with a smoother pharmacokinetic profile. In well controlled 12- to 52-week clinical trials, indapamide SR 1.5 mg/day was well tolerated and reduced blood pressure as effectively as therapeutic dosages of amlodipine, candesartan, enalapril, hydrochlorothiazide or indapamide IR. Indapamide SR was also more effective than enalapril in reducing left ventricular hypertrophy (LVH), and similar reductions in renal end-organ damage, assessed by microalbuminuria, were seen with indapamide SR- and enalapril-based antihypertensive strategies. Indapamide SR provides an effective option for initial antihypertensive monotherapy and a basis for multidrug antihypertensive strategies.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16451099     DOI： 10.2165/00003495-200666020-00011

Source DB:  PubMed          Journal:  Drugs        ISSN： 0012-6667            Impact factor:   9.546


  43 in total

1.  Effects of indapamide, a thiazide-like diuretic, on structure of cerebral arterioles in hypertensive rats.

Authors:  Jean-Marc Chillon; Gary L Baumbach
Journal:  Hypertension       Date:  2004-03-08       Impact factor: 10.190

2.  Indapamide is as effective as captopril in the control of microalbuminuria in diabetes.

Authors:  L M Molyneaux; K A Willey; D K Yue
Journal:  J Cardiovasc Pharmacol       Date:  1996-03       Impact factor: 3.105

3.  Effect of indapamide on left ventricular hypertrophy in hypertension: a meta-analysis.

Authors:  P A Carey; D J Sheridan; A de Cordoue; D Guez
Journal:  Am J Cardiol       Date:  1996-02-22       Impact factor: 2.778

4.  Inhibition of carbonic anhydrase accounts for the direct vascular effects of hydrochlorothiazide.

Authors:  P Pickkers; R S Garcha; M Schachter; P Smits; A D Hughes
Journal:  Hypertension       Date:  1999-04       Impact factor: 10.190

5.  Evaluation of long-term efficacy and acceptability of indapamide SR in elderly hypertensive patients.

Authors:  Gastonea Leonetti; Jean-Paul Emeriau; Heinrich Knauf; Juan Ocon Pujadas; Carlos Calvo-Gomez; Giuseppe Abate
Journal:  Curr Med Res Opin       Date:  2005-01       Impact factor: 2.580

6.  A comparison of indapamide SR 1.5 mg with both amlodipine 5 mg and hydrochlorothiazide 25 mg in elderly hypertensive patients: a randomized double-blind controlled study.

Authors:  J P Emeriau; H Knauf; J O Pujadas; C Calvo-Gomez; G Abate; G Leonetti; C Chastang
Journal:  J Hypertens       Date:  2001-02       Impact factor: 4.844

7.  Growth inhibitory activity of indapamide on vascular smooth muscle cells.

Authors:  P Ganado; E Ruiz; M Del Rio; F Larcher; M Sanz; J R Steinert; T Tejerina
Journal:  Eur J Pharmacol       Date:  2001-09-28       Impact factor: 4.432

8.  Metabolic profile of indapamide sustained-release in patients with hypertension: data from three randomised double-blind studies.

Authors:  P Weidmann
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

9.  Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

Authors:  Aram V Chobanian; George L Bakris; Henry R Black; William C Cushman; Lee A Green; Joseph L Izzo; Daniel W Jones; Barry J Materson; Suzanne Oparil; Jackson T Wright; Edward J Roccella
Journal:  Hypertension       Date:  2003-12-01       Impact factor: 10.190

10.  Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial.

Authors:  Stevo Julius; Sverre E Kjeldsen; Michael Weber; Hans R Brunner; Steffan Ekman; Lennart Hansson; Tsushung Hua; John Laragh; Gordon T McInnes; Lada Mitchell; Francis Plat; Anthony Schork; Beverly Smith; Alberto Zanchetti
Journal:  Lancet       Date:  2004-06-19       Impact factor: 79.321
View more
  7 in total

1.  Genetic polymorphisms of metabolic enzymes and the pharmacokinetics of indapamide in Taiwanese subjects.

Authors:  Teng-Hsu Wang; Cheng-Huei Hsiong; Hsin-Tien Ho; Tung-Yuan Shih; San-Jan Yen; Hui-Hung Wang; Jer-Yuarn Wu; Benjamin Pei-Chung Kuo; Yuan-Tsong Chen; Shung-Tai Ho; Oliver Yoa-Pu Hu
Journal:  AAPS J       Date:  2013-12-20       Impact factor: 4.009

2.  Not just chlorthalidone: evidence-based, single tablet, diuretic alternatives to hydrochlorothiazide for hypertension.

Authors:  George C Roush; Michael E Ernst; John B Kostis; Ramandeep Kaur; Domenic A Sica
Journal:  Curr Hypertens Rep       Date:  2015-04       Impact factor: 5.369

Review 3.  Type 2 Diabetes and Thiazide Diuretics.

Authors:  André J Scheen
Journal:  Curr Diab Rep       Date:  2018-02-05       Impact factor: 4.810

Review 4.  Delapril plus indapamide: a review of the combination in the treatment of hypertension.

Authors:  Luca Cavalieri; Giovanni Cremonesi
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

5.  Complementary mechanisms of action and rationale for the fixed combination of perindopril and indapamide in treating hypertension - update on clinical utility.

Authors:  Vivencio Barrios; Carlos Escobar
Journal:  Integr Blood Press Control       Date:  2010-05-10

Review 6.  Perindopril/Indapamide/Amlodipine in Hypertension: A Profile of Its Use.

Authors:  Yahiya Y Syed
Journal:  Am J Cardiovasc Drugs       Date:  2022-03-08       Impact factor: 3.571

Review 7.  Which thiazide to choose as add-on therapy for hypertension?

Authors:  Vivencio Barrios; Carlos Escobar
Journal:  Integr Blood Press Control       Date:  2014-07-30
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.